Cargando…
Tau and Caspase 3 as Targets for Neuroprotection
The peptide drug candidate NAP (davunetide) has demonstrated protective effects in various in vivo and in vitro models of neurodegeneration. NAP was shown to reduce tau hyperphosphorylation as well as to prevent caspase-3 activation and cytochrome-3 release from mitochondria, both characteristic of...
Autores principales: | Idan-Feldman, Anat, Ostritsky, Regina, Gozes, Illana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369463/ https://www.ncbi.nlm.nih.gov/pubmed/22693678 http://dx.doi.org/10.1155/2012/493670 |
Ejemplares similares
-
A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP
por: Ivashko-Pachima, Yanina, et al.
Publicado: (2019) -
Corrigendum: A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP
por: Ivashko-Pachima, Yanina, et al.
Publicado: (2021) -
Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice
por: Gozes, Illana
Publicado: (2010) -
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein
por: Magen, Iddo, et al.
Publicado: (2014) -
ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect
por: Gozes, Illana, et al.
Publicado: (2018)